



## Press Release

 [View printer-friendly version](#)

### **Bellicum Pharmaceuticals Appoints Dr. William Grossman as Chief Medical Officer**

HOUSTON, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers and other diseases, today announced the appointment of William Grossman, M.D., Ph.D., as Chief Medical Officer, effective February 5. Dr. Grossman joins Bellicum from Genentech/Roche.



Dr. William Grossman named Chief Medical Officer, Bellicum Pharmaceuticals, Inc.

---

“We are excited to have Bill join Bellicum. His expertise in the development of cancer immunotherapy combinations will strengthen our team as we advance and expand our CAR T and TCR therapies for the regulatory filing and potential commercialization of BPX-501 in Europe,” said CEO Rick Fair.

Commented Dr. Grossman: “I am thrilled to join Bellicum at this exciting time. Cellular immunotherapy is transforming how we treat cancer. Bellicum’s novel platform for controlling the activity of T cells will help us improve upon the current generation, extending the benefit of these life-saving therapies to more types of cancer.”

In his most recent role at Genentech, Dr. Grossman served as the Group Medical Director of Cellular Immunotherapy, where he led the global clinical development of TECENTRIQ® in combination with immunotherapy and of cancer immunotherapy combinations across all solid tumor types. Among other responsibilities in this role, Dr. Grossman conceived and led the development of the Phase 1b/2 MORI trial to evaluate cancer immunotherapy combinations more rapidly and efficiently. Previously, he served as Vice President, Research & Clinical Development at Biothera, where he oversaw all clinical development efforts in oncology and immunology. Dr. Grossman has also held leadership roles in research, clinical development, and medical affairs at AbbVie, Baxter Healthcare, and was involved in the development and clinical study of cancer vaccines, immunomodulators, and biologics in oncology.

Prior to joining the industry, Dr. Grossman held various positions with the Medical Department at the Children’s Hospital of Wisconsin, and was Founder and Medical Director of the Immunodiagnostic and Research Laboratory, Professor for Microbiology and Genetic Engineering at the University of Wisconsin-Madison.

Hematology/Oncology/Bone Marrow Transplant Division for the Immunodeficiency. Dr. Grossman earned his M.D. and Ph.D. degrees from Washington University School of Medicine. He completed his medical training in the Division of Pediatric Biology/Medicine at the School of Medicine.

## **Inducement Awards**

The Compensation Committee of the Board of Directors has approved inducement awards which will be granted effective on his start date. The inducement awards consist of a grant of up to 175,000 shares of the Company's common stock priced at the closing price of the grant date of February 5, 2018, and a restricted stock unit for 30,000 shares of common stock. The stock option and restricted stock unit award will be granted subject to the terms of the Company's Incentive Plan. One-fourth of the shares subject to the stock option award will vest on the first anniversary of Dr. Grossman's start date and the remainder of the shares will vest in equal monthly installments thereafter, and 25% of the shares subject to the restricted stock unit award will vest on each anniversary of Dr. Grossman's start date, in each case subject to his continued employment with the Company through each such vesting date and subject to potential vesting acceleration circumstances pursuant to the terms of Dr. Grossman's employment agreement with the Company.

## **About Bellicum Pharmaceuticals**

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its Chemical Induction of Dimerization (CID) technology platform to engineer and control the immune system. Bellicum is developing next-generation product candidates in some areas of cellular immunotherapy, including hematopoietic stem cell transplantation and TCR cell therapies. More information can be found at [www.bellicum.com](http://www.bellicum.com).

## **Forward-Looking Statement**

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "believes," "potential," "proposed," "continue," "designed," "estimates," "anticipates," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty about future outcomes to identify these forward-looking statements. Forward-looking statements include our intentions, beliefs, projections, outlook, analyses or current expectations regarding our intentions, beliefs, projections, outlook, analyses or current expectations regarding other things: our intentions to advance and expand our pipeline, and our intentions to file for BPX-501 in Europe, and if successful, commercialize that product in Europe. Actual results may differ because of cause differences between Bellicum's expectations and actual results as discussed in our filings, including the heading "Risk Factors" in Bellicum's filings with the Securities and Exchange Commission.

limitation our annual report on Form 10-K for the year ended December 31, 2016 and Q for the quarter ended September 30, 2017. Any forward-looking statements that E press release speak only as of the date of this press release. Bellicum assumes no obligation forward-looking statements whether as a result of new information, future events or of this press release.

Source: Bellicum Pharmaceuticals

A photo accompanying this announcement is available at

<http://www.globenewswire.com/NewsRoom/AttachmentNg/4b9e5106-8987-4754>

**Investors:**

Bellicum Pharmaceuticals, Inc.

Alan Musso, CFO

832-384-1116

[amusso@bellicum.com](mailto:amusso@bellicum.com)

**Media:**

BMC Communications

Brad Miles

646-513-3125

[bmiles@bmccommunications.com](mailto:bmiles@bmccommunications.com)



Source: Bellicum Pharmaceuticals, Inc.

**About Us**

[Overview](#)

[Management Team](#)

[Board of Directors](#)

[Clinical Advisory Board](#)

[Careers](#)

[Contact Us](#)

**Product Candidates**

[Pipeline](#)

[BPX-501](#)

[BPX-601](#)

[BPX-701](#)

[CD19 Program](#)

**Technology**

[Overview](#)

[CaspaCIDE](#)

[GoCAR-T](#)

[Scientific Literature](#)

[Posters and Abstracts](#)

**Clinical Trials**

[BPX-501 in Blood Cancers & Inherited Blood Disorders](#)

[BPX-601 \(GoCAR-T\) and BPX-701 \(TCR\)](#)

**Investors & Media**

[Investor Center](#)

[Home](#)

[News & Events](#)

[Stock Information](#)

[Financial](#)

[Information](#)

[Corporate](#)

[Governance](#)

[Shareholder](#)

[Services](#)

Copyright © 2018 Bellicum  
Pharmaceuticals Inc. All Rights  
Reserved

[CONTACT US](#)

[PRIVACY POLICY](#)

[TERMS OF USE](#)